Genomic insights into ayurvedic and western approaches to personalized medicine by Prasher, Bhavana et al.
c© Indian Academy of Sciences
REVIEW ARTICLE
Genomic insights into ayurvedic and western approaches to personalized
medicine
BHAVANA PRASHER1∗, GREG GIBSON3 and MITALI MUKERJI1,2∗
1CSIR Ayurgenomics Unit-TRISUTRA, CSIR-Institute of Genomics and Integrative Biology, New Delhi 110 020, India
2Genomics and Molecular Medicine, CSIR-Institute of Genomics and Integrative Biology, Mathura Road,
New Delhi 110 020, India
3School of Biology and Center for Integrative Genomics, Georgia Institute of Technology, Atlanta, GA 30332, USA
Abstract
Ayurveda, an ancient Indian system of medicine documented and practised since 1500 B.C., follows a systems approach that
has interesting parallels with contemporary personalized genomic medicine approaches to the understanding and manage-
ment of health and disease. It is based on the trisutra, which are the three aspects of causes, features and therapeutics that are
interconnected through a common organizing principle termed ‘tridosha’. Tridosha comprise three ascertainable physiologi-
cal entities; vata (kinetic), pitta (metabolic) and kapha (potential) that are pervasive across systems, work in conjunction with
each other, respond to the external environment and maintain homeostasis. Each individual is born with a specific propor-
tion of tridosha that are not only genetically determined but also influenced by the environment during foetal development.
Jointly they determine a person’s basic constitution, which is termed their ‘prakriti’. Development and progression of dif-
ferent diseases with their subtypes are thought to depend on the origin and mechanism of perturbation of the doshas, and
the aim of therapeutic practice is to ensure that the doshas retain their homeostatic state. Similarly, western systems biology
epitomized by translational P4 medicine envisages the integration of multiscalar genetic, cellular, physiological and environ-
mental networks to predict phenotypic outcomes of perturbations. In this perspective article, we aim to outline the shape of
a unifying scaffold that may allow the two intellectual traditions to enhance one another. Specifically, we illustrate how a
unique integrative ‘Ayurgenomics’ approach can be used to integrate the trisutra concept of Ayurveda with genomics. We
observe biochemical and molecular correlates of prakriti and show how these differ significantly in processes that are linked
to intermediate patho-phenotypes, known to take different course in diseases. We also observe a significant enrichment of the
highly connected hub genes which could explain differences in prakriti, focussing on EGLN1, a key oxygen sensor that dif-
fers between prakriti types and is linked to high altitude adaptation. Integrating our observation with the current literature,
we demonstrate how EGLN1 could qualify as a molecular equivalent of tridosha that can modulate different phenotypic out-
comes, where hypoxia is a cause or a consequence both during health and diseased states. Our studies affirm that integration
of the trisutra framework through Ayurgenomics can guide the identification of predisposed groups of individuals and enable
discovery of actionable therapeutic points in an individualized manner.
[Prasher B., Gibson G. and Mukerji M. 2016 Genomic insights into ayurvedic and western approaches to personalized medicine. J. Genet.
95, 209–228]
Introduction
Ayurveda is an Indian system of predictive, preventive, per-
sonalized and promotive medicine documented and practised
since 1500 B.C. Its primary aim is maintenance of health
in healthy people and alleviation of disorders in diseased
people (Sharma 1981, 1999). In this sense it is no different
from the contemporary efforts that use molecular diagnos-
tics for the purposes of predictive health and personalized
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medicine. Ayurveda describes the subject matter into three
major categories termed ‘trisutra’, meaning the three inter-
connected aspects of causes (hetu), features (linga) and ther-
apeutics (aushadha) both for healthy and diseased people
(Sharma 1981). The question thus arises as to whether there
are molecular and genomic correlates of trisutra.
Understanding the molecular mechanisms of a disease that
can be rationalized to design effective drugs and improve hu-
man health care remains a fundamental goal of medical sci-
ence. In medical terms, a disease is defined as a condition that
demonstrates adverse effects on normal human physiology
Keywords. ayurgenomics; human individuality; system biology; tridosha; P4 medicine; trisutra; prakriti.
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under the influence of various factors, which are mainly char-
acterized as either genetic or environmental. Since a dis-
ease is characterized by its symptoms, the current principle
of medical science seeks its cure in a symptom-guided man-
ner, which often ignores the process of disease onset. Symp-
toms are the outcomes of an evolutionary process that a
disease onset adopts spanning the genotype–phenotype space
of a given individual. It therefore becomes imperative to
comprehend such genotype–phenotype relations of a given
human individual in the context of its environment. In the
posthuman genome sequence era, our understanding of
genotype–phenotype relation has improved significantly.
Decades of investigations suggest that phenotypic manifes-
tation is a consequence of an enormous amount of com-
plexity due to the underlying orchestration between various
biological components such as DNA, RNA, protein and
metabolites involved in various cellular processes that are
responsive to the environment. Effects can be seen across
the range from single-cells to epidemiology. While the cur-
rent systems-level framework is capable of deconvoluting
the complexity of disease process in a discrete manner, it
however remains challenging to comprehend such complex
relations in a time-dependent manner. Network medicine is
evolving as an emerging area of research as we begin to com-
prehend the knowledge of networks in biological systems
and evolve the tools of systems biology (Oltvai and Barabási
2002; Loscalzo et al. 2007; Agustí et al. 2011; Barabási et al.
2011; Loscalzo and Barabási 2011; Fabbri et al. 2012).
We would argue that recognition of the underlying
systems biology has been effective in the translation of net-
work medicine into clinical practice of Ayurveda for thou-
sands of years in India. Evidence from the textual references
(Sharma 1981, 1999) suggest that this field has evolved fol-
lowing intensive observations spanning long period of time
in large number of individuals which has lead to establish-
ment of tenets that are still contemporary (figure 1). Today,
this practice continues in India side-by-side with western
medicine, with the ongoing training of ayurvedic doctors
and, opening of clinics and hospitals as a prominent feature
of Indian healthcare. The concepts and practice of Ayurveda
resonate with the aims, observations and the promise of con-
temporary P4 medicine; it is predictive, preventive, person-
alized and participatory medicine (Hood and Friend 2011;
Tian et al. 2012; Agustí 2013). Currently the science of net-
work medicine is primarily observational, involving big data
and large amounts of correlations (Barabási 2007; Park et al.
2009; Suthram et al. 2010; Agustí et al. 2011; Barabási et al.
2011; Vidal et al. 2011; Li et al. 2014). This review high-
lights the Trisutra aspects of Ayurveda, its relevance and
contemporariness in systems medicine.
The aim of this study was to propose a theoretical frame-
work of Ayurveda that can help systematize these observa-
tions to have a comprehensive understanding and a foundation
for P4 medicine. We start by introducing the concepts of
Ayurveda, using the Sanskrit terms as described in the clas-
sical and most widely cited ayurvedic literature, namely,
the English translations of Charaka samhita (Sharma 1981),
Sushruta samhita (Sharma 1999) and Ashtanga sangraha
(Srikanthamurthy 1992). To specifically direct the reader to
the relevant part of these books and to highlight the extent of
documentation available in these ancient texts, we have fol-
lowed the convention described in table 1. Subsequently, we
discuss three potential modes of synthesis of the principles
of Ayurveda with contemporary genomic medicine, namely:
(i) stratification of heterogeneous populations to enhance the
effectiveness of genetic association studies, (ii) gene expres-
sion profiling to find molecular correlates of tridosha, the
physiological entities responsible for understanding human
individuality, and (iii) discovery of genetic variants that may
contribute to development of phenotypes that are key to
ayurvedic classification.
Ayurveda: translational medicine with systems
approach
The personalized approach of Ayurveda begins with the
fundamental understanding of interindividual differences in
baseline health states, starting with their development vis-a-
vis determinants and contributing factors. Responsiveness to
environment and robustness of the systems are also largely
determined by baseline health states. This, further feeds on
to the variability in disease susceptibility, course of clini-
cal presentation and progression (1: C.I.1, C.Vi.8; C.Su.10 &
C.Vi.6). These baselines of health also guide the recommen-
dations made by ayurvedic practitioners regarding therapeu-
tic regimens both for maintenance and promotion of health
as well as for alleviation of disease conditions. The latter
include interventions regarding the line of treatment, choice
of drugs, and their dosage and mode of delivery, all of which
are tailored to disease subtype, severity and stage (1: C.Vi.8).
Ayurveda also considers the dynamicity of an individ-
ual’s environment, both internal (age, basic constitution,
metabolic capacity, mental state, etc.) and external (time,
place, season) for assessment of the levels of perturbation
from his/her basic homeostatic state, and in turn the selec-
tion of drugs and dietary regimen (1: C.I.1 & C.Sa.6). This,
explains the use of word ‘healthy’ and ‘diseased’ instead
of ‘health’ and ‘disease’ in the descriptions of trisutra in
Ayurveda (1: C.Su.1 & C.Su.30; 2: S.Su.1).
Tridosha: common organizing principle shaping human
individuality
The interrelatedness of internal and external environment
is due to a common origin, panchamahabhuta (five funda-
mental elements) whose biological effects in humans are
explained in terms of a unifying organizing principle called
the tridosha (3: A.S.Su.20). Tridosha perform all major phys-
iological functions of the body starting from fertilization
through development, continuing later in life until ageing
and death. Tridosha comprises three ascertainable physio-
logical entities, namely, vata (kinetic), pitta (metabolic) and
kapha (potential) that are pervasive across systems, work
in conjunction with each other, and respond to external
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Figure 1. Tridosha as a common organizing principle in health and disease. Concept of personalized medicine of Ayurveda based on
prakriti can allow integration of population genomic approaches (a) with system’s understanding of physiological networks, (d) through
the molecular analysis of common underlying principle of tridosha (b and c). Figures b and c represents the tridosha concept in human
physiology. The three vertices of the triangle represent vata, pitta and kapha axes. Figure b represent the static state (praakrit) and c the
dynamic (vaikarik) represented by yellow and red triangles respectively. The dynamic component can fluctuate along any of the three axes
in response to intrinsic and extrinsic stimuli. Health state depicted as the adaptive space is constrained within the limit depicted by the grey
triangle beyond which, is the diseased state. Disease onsets when the dynamic component crosses the threshold towards any of the vertices
as depicted in b. Figure d depicts all levels of organization where prakriti tridosha proportions can bring about variability. An individual is
more likely to cross the threshold of adaptive space in the direction of its own prakriti.
environmental conditions to maintain homeostasis (1: C.Su.1
& C.Su.18; 2: S.Su.21; 3: A.S.Su.19 & A.S.Su.20). Distinct
properties and functions have been ascribed to each dosha
(Prasher et al. 2008). For instance, vata (V) contributes
to manifestation of shape, cell division, signalling, move-
ment, cognition and excretion of wastes. It is also consid-
ered to be an initiator of the activities of kapha (K) and
pitta (P) (1: C.Su.12 & C.Ci.28). Pitta is primarily respon-
sible for metabolism, thermoregulation, energy homeostasis,
pigmentation, vision and host surveillance (1: C.Su.12&18;
3:A.S.Su.19,20). Kapha is responsible for anabolism,
growth and maintenance of structure, storage and stability
(1: C.Su.12 & C.Su.18; 3; A.S.Su.1920).
Each individual is born with a specific proportion of tri-
dosha (V, P and K) that determines his/her basic constitu-
tion, which is termed their ‘prakriti’ (1: C.Vi.8; 2: S.Sa.4; 3:
A.S.Sa.8). The proportions of tridosha in the gametes of the
parents at the time of fertilization contribute to the process of
foetal development, and they shape and influence multisys-
temic phenotypic traits, including each person’s responsive-
ness to extrinsic and intrinsic cues, thereby influencing their
susceptibility to diseases (1: C.Vi.8; 2: S.Sa.4; 3: A.S.Sa.8;
figure 2).
The proportions of VPK in a prakriti are not only genet-
ically determined in the gametes (shukra shonita), but also
influenced by diet, life style and age of the transmitting
parents as well as maternal diet and environment during
foetal development (matur-ahar-vihara, kala garbhashaya,
mahabhutavikara). Genetic aspects are a cumulative effect
of ethnicity (jati-prasakta), familial aspects (kula-prasakta)
and geoclimatic (desha-anupatini) conditions including indi-
vidual specific aspects (pratyatmaniyata). Geoclimatic con-
ditions exert their effects during foetal development as well
as on phenotypic manifestations in later life (figure 2).
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Table 1. The convention followed for original textual references cited in the text.
Collective name of group of chapters Example references from all texts
Text name (predominantly dealt subject) dealing with different subjects
Charaka samhita (C.) Sutra sthana (Su.) C.Su.1, first chapter of Charaka
(conceptual framework and abridged samhita sutra sthana;
version of entire compendium) C.Vi.8, eighth chapter of Charaka
samhita vimana sthana
Sushruta samhita (S.) Sharira sthana (Sa.) S.Ni.1, first chapter of Susruta
(anatomy, physiology and samhita, nidana sthana
developmental biology)
Nidana sthana (Ni.)
(principles of etiopathogenesis
including clinical features of diseases)
Ashtanga samgraha (A.S.) Vimana sthana (Vi.) A.S.Sa.4, fourth chapter of
(principles of analysis for disease, ashtanga samgraha, sharira sthana;
drug and individuals for personalized A.S.Su.20, twentieth chapter of
management of health and disease) ashtanga samgraha sutra sthana
Chakrapani commentary (Ck) Indriya sthana (I.) Ck on C.Su.7= Chakrapani’s
(clinical methods for assessment of commentary on seventh chapter of
prognosis and outcome of disease) Charaka samhita sutra sthana
Chikitsa sthana (Ci.)
(principles of internal medicine
including regenerative and
reconstructive surgery)
Dalhana commentary (Dl) Kalpa sthana (Ka.) and Siddhi sthana (Si.) Dl on S.Sa.4, Dalhana’s
(pharmaceutical processing of commentary on fourth chapter
medicinal formulations mainly for Susruta samhita sharira sthana
panchkarma (cleansing/regenerative)
therapies)
These textual references are available in English translations in Sharma 1981, Sharma 1999 and Srikanthamurthy 1992 and have been
referred with the number 1, 2 and 3 respectively in the text citations. For example ‘1: C.Vi.8’ would be a citation available in reference ‘1’
i.e. P.V. Sharma’s English translation of Chapter 8 of Charaka Samhita Viman Sthana.
Figure 2. Mechanism of development and expression of prakriti in an individual with the factors governing them at different stages:
prenatal, developmental and at later stages of life. The dynamicity of proportions of tridosha during day, age and season is depicted for a
representative vata prakriti.
Thus, prakriti is a consequence of the cumulative effects
of genetic and epigenetic factors, ethnicity, heritability, geo-
climatic adaptations, age, time and season which have all
been independently shown in modern times to affect human
phenotypes and its responsiveness to external environment
(1: C.I.1 & C.Vi.8; 3: A.S.Sa.8).
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If the VPK proportions exceed allowable limits of varia-
bility, it is possible that a viable foetus does not develop. Sim-
ilarly, disproportions in localized systems/tissues may lead
to malformations/developmental defects (garbha vikriti) of
that system. The proportions of VPK that are physiologically
viable only lead to development of foetus with correspond-
ing prakriti (1: C.Su.7 and Ck commentary ; 2: S.Sa.4 and Dl
commentary).
Tridosha at different levels of organization in
development and health
Prakriti tridosha governs the entire process of development
including building of the basic body tissues (seven dhatus).
The tridosha and dhatus together build organs (koshthanga)
and systems (srotas). Each organ system is developed with
its own characteristic proportions of VPK and basic body
tissues in accordance with their physiological functions (1:
C.Su.20 & C.Ci.28; 2: S.Sa.4; 3: A.S.Su.19, 20). The cumu-
lative effect of differential proportions of tridosha (prakriti)
would thus be reflected in multisystem attributes observable
at various levels of anatomy, physiology and mental apti-
tude as well as in response to diet, environment, life style
and stress. Thus variable states of health (prakriti) are an
outcome of the different proportions of the tridosha dur-
ing development, and these remain invariant in an individ-
ual. The observation that each organ system has its own
proportions of VPK will likely complicate efforts to study
the molecular correlates of prakriti, since it would presum-
ably be necessary to perform genomic profiling on each
tissue.
Phenotypic diversity, according to Ayurveda, is a con-
sequence of a continuum of the relative proportions of
VPK, resulting in seven possible constitutional types namely
vata (V), pitta (P), kapha (K), vata-pitta (VP), pitta-kapha
(PK), vata-kapha (VK) and vata-pitta-kapha (VPK). The
first three are considered as phenotypic extremes, exhibit-
ing readily recognizable phenotypes (table 2 and 1: C.Vi.8;
2: S.Sa.4; 3: A.S.Sa.8). It is worthwhile to emphasize
that each of these states are healthy, as they are systems
that have developed and tuned to adapt to the person’s
basal levels of VPK. However, perturbation from these
levels predisposes people to specific diseases (2: S.Sa.4;
3: A.S.Sa.8; figures 1 and 3). For example, vata prakriti
is likely to cross the thresholds of vata more readily
than any other prakriti types (1: C.Vi.6). Prakriti assess-
ment in an individual is carried out with the phenotypes
described in Ayurveda and incorporated in questionnaire
(Prasher et al. 2008). It takes into account the anatomy,
physiology, metabolism, response to diet and environ-
ment, physical activities and movements, higher functions
of brain and psychosocial behaviour etc. The comprehen-
sive extent to which each of these attributes is examined
is provided in table 3. This phenotype scaffold keeps in
context the ancestry, genetic background and geoclimatic
conditions as well as the age of the individual during
assessment.
Dynamic component of tridosha: links between health and
disease, in response to internal and external environment
In an individual, the VPK comprises both static and dynamic
components. The proportions of VPK that govern the devel-
opmental process and shape the prakriti of an individual
are fixed at the time of birth and are called praakrit (static)
doshas (3; A.S.Sa.8) (figure 2). These levels of VPK are
replenished through nutrition with specific diets that are suit-
able for maintenance of prakriti proportions of VPK (1:
C.Su.28). The doshas continue to perform their physiolog-
ical function throughout a person’s lifetime and maintain
homeostasis in harmony with the external environment (1:
C.Sa.4 & C.Su.18, 20; 2: S.Su.15; 3: A.S.Su.19,20). VPK
also oscillate with cues from sunlight (surya), moon (soma)
and wind (anil), which are expressed as rhythmic/cyclical
changes of day, night and seasons (aho ratri ritu) (1: C.Su.12
& C.Su.6; 3: A.S.Su.1 & A.S.Su.4; figure 3). Their levels
are also influenced by internal rhythms such as sleep, stages
of digestion and metabolism (nidra, avasthapaka, nishtha-
paka) as well as ageing (vaya) and other lifestyle practices
(Vihara) (1: C.Ci.15; 3: A.S.Su.1). This dynamic component
of the dosha is called vaikarika, and its patterns are deter-
mined by an individual’s prakriti tridosha (praakritaa vikru-
tanam beejbhoota) (Srikanthamurthy 1992). This in turn is
manifested as rhythmic and temporal expression of prakriti
phenotypes apportioned to the time (kalanupatini) as well
as age (vayonupatini) components (figure 3). These tempo-
ral doshic proportions also contribute to interindividual dif-
ferences in the overall physical and mental strength, toler-
ance for exercise, dietary habits, metabolism and excretion
tendencies (table 2). For instance, as an effect of old age,
vata increases in every individual. However, a vata prakriti
person would exhibit the effects of elevated vata such as
erratic metabolism and excretion, lack of sleep etc., more
intensively and the onset could also be earlier. Six basic
tastes (sweet, sour, salty, bitter, pungent and astringent) have
been ascribed to food and drugs wherein, a group of three
tastes are described to increase each dosha and the remain-
ing three decrease them, thereby making them suitable or
unsuitable for corresponding prakriti. For instance bitter,
astringent and sweet keep pitta in check whereas sour, salty
and pungent items are not suitable for pitta and accordingly
ayurvedic practitioners make dietary recommendations with
these tastes in mind (1: C.Su.1, C.Vi.1, C.Su.7 18: A.S.Sa.8).
Also the suitability of season, geography, food and climate
vary amongst prakriti types and the peak activity hours also
differ between prakriti. Just like the circadian rhythms, the
proportions of tridosha vary temporally throughout the day
with different peak times of vata, pitta and kapha in a 12 h
cycle and also with the seasons (figure 3). Importantly, the
tridosha are restrained within normal limits in health while
perturbations beyond an individual’s threshold (praakrit plus
allowable vaikarik component) lead to diseased (vikriti)
states (3: A.S.Sa.8). The robustness or fragility of the sys-
tem depends upon whether a person has balanced or extreme
dosha proportions in the basic constitution respectively. This
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Table 2. Distinguishing features of predominant prakriti types: phenotype scaffolds (1: C.Vi.8; 2: S.Sa.4; 3: A.S.Sa.8).
Features Vata Pitta Kapha
Anatomical
Body frame Thin Medium Broad
Body build and Weakly developed Moderate Well developed
musculature
Skin Dry and cracked Soft, thin, with Smooth and firm,
tendency for moles, clear complexion
acne and freckles
Hair Dry, thin, prone to Thin, oily, early Thick, smooth and
breaks graying firm
Physiological
Appetite for food and Frequent, variable and Higher digestive Regular and stable
digestive capacity irregular food habit capacity for food and food habits with low
water consumption amount; lower
digestive capacity
Taste preference Sweet, sour, salty Sweet, astringent, Sweet, bitter, pungent
bitter and astringent
Thirst and perspiration Variable High Low
Body odour Mild Strong Very less
Body temperature Low or variable High Low
Weight gain Difficulty in gaining Gain and loose easily Tendency to obesity
Bowel habit tendency Irregular towards Loose motion None
constipation
Sleep (amount and quality) Less and shallow Moderate/sound High and deep
Physical activities and Excessive and brisk Moderate/spontaneous Less mobile
movements
Tolerance for seasonal Cold intolerant Heat intolerant Endurance for both
weather
Metabolism of toxic Moderate Quick Poor
substances
Ageing Fast Moderate Slow
Higher mental functions
Communication Talkative Sharp, incisive Less vocal with good
communication with communication skills
analytical abilities
Initiation capabilities Quick, responsive and Moderate, upon Slow to initiate new
enthusiastic conviction and things
understanding
Memory Quick at grasping and Moderate grasping Slow grasping and
poor retention and retention good at retention
Disease susceptibility, resistance and healing power
Disease Developmental, Ulcers, bleeding Obesity, diabetes,
predisposition/poor neurological, disorders, skin atherosclerotic
prognosis dementia, movement diseases conditions
and speech disorders,
arrhythmias
Distinguishing features of predominant Prakriti types: phenotype scaffolds (1: C.Vi.8; 2: S.Sa.4; 3: A.S.Sa.8). The numbers 1, 2 and 3 refer
to the English translations of Sharma 1981, Sharma 1999 and Srikanthamurthy 1992, respectively.
resonates with the fundamental strategies of physiological
adaptation in living organisms (Baffy and Loscalzo 2014).
The three most contrasting types (pitta, vata and kapha) are
the most vulnerable as they are likely to cross the thresholds
of normal limits more readily (1: C. Su.7 & C.Vi.6). It can be
seen that the assignment of an individual’s prakriti represents
predictive health in contemporary terminology.
Tridosha in disease development: systems understanding
Baseline prakriti tridosha (homeostatic state) in an individ-
ual is a prelude for dynamic states of health in response
to extrinsic as well as intrinsic factors and evolution of disea-
sed states (perturbed state of doshas). Correspondingly,
the development and progression of different diseases de-
pends upon the origin (Hetu) and mechanism of perturbation
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Figure 3. Spatio-temporal dynamics of tridosha. (a) Three baseline patterns of tridosha in vata, pitta and kapha dominant prakriti types.
(b) Age-dependent expression of kapha, pitta and vata determined by baseline prakriti doshas. This is not equal for all prakriti as depicted
by the size of red triangle. (c) Temporal responsiveness of tridosha to different seasons in a rhythmic manner. The gradual rise, peak and
fall of VPK in different seasons is also depicted (lower panel). (d) Time-dependent oscillation of VPK during 24-h day night cycle in a vata
dominant individual. The shaded area denotes the peak time of dosha. The static state (praakrit) and the dynamic (vaikarik) are represented
by yellow and red triangles, respectively.
(Samprapti - Vyadhi janaka dosha vyapar vishesha) of
Doshas and their site of interaction and manifestation
(dushya and sthana) (1: C.Ni.1). The process of disease
development takes six major steps (shat kriyakaala) and
exhibits some preclinical features that provide opportunities
for intervention at every step. The steps include initia-
tion of dosha accumulation (sanchaya), dosha aggravation
at a site (prakopa), spread of dosha into other tissues/systems
(prasara), their interaction and effect on local target sys-
tems (sthana samshraya), leading to disease manifestation
(vyakti), and further differentiation (bheda) (2: S.Su.21).
Initiation of the disease process and its development into
specific subtypes depend upon the nature and severity of
external etiological factors and their interaction with VPK.
This leads to perturbation of specific aspects of dosha or
their combinations. The origin and mechanism of perturba-
tion of doshas, strength and kinetics of their interaction with
body tissues/organs and systems are the major determining
factors for clinical manifestation of disease, its severity and
progression. This again depends on baseline robustness or
vulnerability of the target systems as well as specific affin-
ity of etiological factors to target them. Other influencing
factors include the time and place during which the dosha
involved might assume strength as a natural consequence of
its rhythmicity (1: C.Su.28 & C.Ni.4).
In the absence of intervention at any of these steps, pertur-
bation continues to progress until the disease has manifested,
or until advanced complications (upadrava)/comorbidities
(vyadhi sankara) appear, through emerging entropy of tri-
dosha and involvement of other systems in the process
(1: C.Ni.8). Interestingly, comorbidities have also been
described as an outcome of faulty management of disease
without proper consideration of personalized aspects of clin-
ical medicine (1: C.Ni.8). This is in contrast to the common
belief that traditional medicines can all be administered ‘off
the shelf’ without any concern for their side-effects.
While this conceptualization forms the common under-
lying principle of pathogenesis, each disease has been
described to have a specific set of etiological factors, dosha
subtypes, with characteristic involvement of particular organ
systems leading to presentation of defined clinical pheno-
types and advanced complications. For example, prameha, a
broad group of disorders that include diabetes, can be caused
by kapha with 10 subtypes, pitta with six subtypes, and vata
with four subtypes, giving different clinical presentations in
colour and odour of the urine (1:C.Ni.4 & C.Ci.6). Also, in
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Table 3. Details of attributes included in the questionnaire for assessment of different phenotypic aspects of prakriti (1: C.Vi.8; 2: S.Sa.4;
3: A.S.Sa.8).
A. Clinical assessment parameters for physical body parts
Shape, symmetry, Overall body frame, as Head, forehead, face, eyebrows, eyes, lips, jaws, teeth, hands,
size, height/ well as individual body palms, legs, soles, joints, shoulder, chest, nails, etc.
length/breadth parts
Appearance Skin Lustrous, wrinkled, moles, marks, pimples, freckles, cracks, etc.
Eye Shiny/dim/dry or dull
Sclera with milky white, reddish tinge or muddy appearance
Colour Teeth Milky white/yellowish/dull or blackish
Eye Light brown/dark brown/black/grey/green/ blue
Palate, palms and soles Dark/reddish/pale yellow/pink
Skin Fair/dark/reddish/pale yellow/pink/wheatish/golden/fresh
colour/dusky
Body hair Black/dark brown/light brown/dusky/copper/ blonde
Scalp hair Black/dark brown/light brown/dusky/copper/blonde
Nature Skin Dry/oily/normal/seasonal or variable
Type: thick/thin
Lips, palm and sole Smooth/soft/rough; firm; cracked; wrinkled
Nails Smooth/soft/rough; firm; cracked (brittle); flat/convex
Scalp hair Dry/oily/normal/seasonal or variable
Texture Skin Smooth/rough/coarse
Firm/loose
soft/hard
Scalp hair Type: thick/thin; straight/wavy/fizzy or curly
Feel: coarse/smooth; soft/hard
Response Scalp hair Graying/falling/breaking
Growth/ bulk Dense/moderate/scanty; baldness (yes/no)
B. Physiological parameters: body metabolism and excretion-related clinical parameters
Metabolism Appetite, thirst and Frequency, regularity, amount, variability in response to diet
digestive power
Bowel and bladder Frequency, regularity, amount, variability in response to diet
habits
Body temperature, Low, medium, high, variable
prespiration and odour
Sleep Quantity Low, medium, high, variable
Quality Shallow, deep, sound
Body weight changes Frequent fluctuations, difficulty in gaining, difficulty in loosing
C. Response to diet and environment
Food Like/do not like Sweet/sour/salty/bitter/pungent/astringent; cold/warm; dry/oily
Suit/do not suit
Weather Preference Temperature/humidity
Health problem
Season Preference Summer/early winter/late winter/autumn/
Health problem spring/rainy/none/season transition
D. Physical activities and movements
Walking and working Speed, style/accuracy, amount and quality
Eyes, eyebrows, jaw, lips, tongue, head, shoulder, hands, legs
Overall strength assessment Physical, mental, resistance power, healing power
E. Voice, speech and communication
Voice Quality Low/feeble/weak/broken/rough/deep/good
tone/sharp/clear/high pitched/loud/soft, pleasing
Amount Less/moderate/excessive
Speech Speed Quick or fast or brisk/medium/slow/variable
Consistency Consistent/inconsistent/moderate
Content of speech Thoughtfulness Well guarded well thought of/ wavering easily deviated/ sharp
accurate spontaneous
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Table 3 (contd)
Style Convincing/argumentative/sweet & pleasing to ears/avoid
confrontations/deviated from main topic/irrelevant in between
F. Higher functions of brain and psycho-social behaviour
Speed Memorizing, forgetfulness, recalling, initiation, making new friends, anger, irritability
Retaining, planning, execution, achieving ends, retaining friends, anger, forgiveness,
generosity, faith and beliefs
Memory type Olfactory, auditory, tactile, gustatory, visual
Details of attributes included in the questionnaire for assessment of different phenotypic aspects of prakriti (1: C.Vi.8; 2: S.Sa.4; 3: A.S.Sa.8).
The numbers 1,2 and 3 refer to the English translations of Sharma 1981, Sharma 1999 and Srikanthamurthy 1992 respectively.
spite of the existence of 20 different varieties of prameha,
this group of disorders analogous to metabolic syndrome
has the initial involvement of dosha (kapha) and premature
fat/adipose tissue (bahu abaddha meda) as the seat of patho-
genesis, which can then take alternate trajectories to different
subtypes. Ayurveda examines the variability in disease not
only in terms of stage and severity, but also differences in
triggers causing onset of pathogenesis that could result in
specific subtypes of the disease (1:C.Su.19, C.Ni.1&C.Vi.8).
This is in contrast to the practice of modern medicine where
the clinical symptoms are analysed in great detail, but base-
line variability of the individual as well as the initial triggers
of pathogenesis leading to differential course of disease are
not well understood.
Tridosha and prakriti
Personalized management of health: Ayurveda advocates
special types of therapy for enhancement of regenerative
potential (rasayana) and reproductive health (vajikarana) of
an individual (1: C.Ci.1). These therapies are administered
only after cleansing the body of toxins, and accumulated
tridoshas. Dynamic states of health are maintained through
personalized recommendations of diet, exercise, rest, sleep
and other lifestyle practices with respect to time and amount
based on an individual’s prakriti, also considering his or her
age, place, season etc. (1:C.Sa.6 & C.Vi.1). This includes
periodic cleansing of the body during rhythmic peaks of
VPK (kapha during spring; pitta during autumn and vata
during monsoon season, figure 3) to prevent accumulation
of excess tridoshas and other excretory metabolites (malas)
(1: C.Su.6 & C.Su.7; 2: S.Su.6). This is carried out follow-
ing specific protocols which include a preparatory phase for
the system to expel the toxins, followed by a postproce-
dural care that ensures the proper restoration and rejuve-
nation (1: C.Su.15 & C.Si.1). This preemptive approach of
Ayurveda towards maintenance of health is aimed at prevent-
ing the manifestation of diseases to which an individual is
predisposed (ajaatanam vikaranam anutpatti) (1: C.Su.7).
Rasayana therapy by definition is meant to enhance the
strength and robustness of the systems by augmenting their
cellular functions (1: C.Ci.1; 2: S.Ci.27). It improves the
higher functions of brain and mental faculties like cognition,
memory, speech, intelligence, etc. It thus acts as a preventive
therapy for ageing and age-related disorders, increasing the
longevity of an individual. This at times is also adminis-
tered in the advanced stages of diseases where the recovery
from them is expected to come through tapping the regener-
ative potential of the system rather than through corrective
mechanisms of drugs (Sharma 1981; Srikanthamurthy 1992;
Sharma 1999).
Personalized management of diseases: The goal of medical
treatment is the alleviation of disorder in a manner that does
not provoke pathogenesis in others or disturb healthy tissues.
For this purpose, Ayurveda describes clinical examination
points pertaining to disease and diseased individual, by a
physician, to analyse not only the nature and strength of dis-
ease as well as that of the individual to select the appropriate
line of treatment and usage of drug (1: C.Vi.1 & C.Vi.8; 2:
S.Su.35). Thus a triad of disease, diseased and drug, (roga,
rogi, aushadha) as described below is analysed for delivery
of personalized medicine:
• Examination of variables related to disease (vikriti parik-
sha) which include presentation of clinical subtypes,
severity and stage (vyadhi avastha), strength and multi-
plicity of triggers, etiological factors both extrinsic (hetu)
and intrinsic (dosha-dushya).
• Diseased individual-related baseline prakriti, suitability
towards therapy and drugs (satmya, agni, koshtha), age of
the individual.
• Present status of health-physical (deha bala-sara,
vyayama shakti etc.), psychological (chetas bala) and
individual’s present status of metabolism and waste clear-
ance organs (agni bala and koshtha), including external
environmental factors like geoclimatic (desha) and time
(kaala).
Ayurveda has also laid down guidelines for integration
of a personalized approach even in the process of devel-
opment of drugs (1: C.Vi.8). This is done through basic
understanding of nature and activities of drugs, employ-
ment of pharmaceutical processes for development of spe-
cific dosage form keeping in view of the desired biolog-
ical activity, with methods for their storage and preserva-
tion (1:C.Su.4, C.Su.26, C.Ka.1-12). The details of specifi-
cation with which a pharmacological action of the drug is
to be understood is as follows: ‘such a drug formulation
when administered in a given dose, for specific type of dis-
ease, in a particular individual, will bring the perturbed dosha
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back to homeostasis either through excretion or titration’ (1:
C.Vi.8.87). Concurrent advancements in the area of phar-
maceutical sciences and pharmacology enabled the physi-
cians to make personalized variations also in the delivery
of therapeutics with respect to routes, time and modes of
administration.
Trisutra thus is an operational framework of network
medicine both in the context of healthy and diseased. It
integrates the understanding of networks in physiology in
the context of spatio-temporal dynamics and translates them
for the development of predictive as well as personalized
preventive and therapeutic medicine.
Integration of Trisutra framework to systems
biology and network medicine
Understanding human individuality: threading dimensions of
variability
The unanticipated extent of human genome variation as cat-
alogued in numerous genomic databases has nearly ruled
out the possibility of defining or reconstructing a reference
healthy human from mere reading of the genomic sequences
(The 1000 Genomes Project Consortium 2012; Olson 2011,
2012). There are now nearly 38 million SNPs, 1.4 million
indels, 14 k deletions and 20 k structural variations repre-
sented in the variation databases (The 1000 Genomes Project
Consortium 2012). The majority of the common variations
are shared across world populations (The 1000 Genomes
Project Consortium 2010, 2012). However, the frequencies
of these variations differ between populations and among
individuals as a consequence of migration, admixture, nat-
ural selection, pathogen load or cultural practices (Tishkoff
and Verrelli 2003; Tishkoff et al. 2007; Coop et al. 2009;
The 1000 Genomes Project Consortium 2010; Jablonski and
Chaplin 2010; Fumagalli et al. 2011; Hancock et al. 2011;
Patterson et al. 2012; Fu and Akey 2013). Genetic variability
gives rise to enormous combinatorial possibilities whose
effects ramify through the genetic, transcriptional, biochem-
ical, proteomic, metabolic and higher order physiological
network levels, impacting the entire health of an individual
(Jeong et al. 2000; Rual et al. 2005; Stelzl et al. 2005;
Pan et al. 2008; Park et al. 2009; Hawkins et al. 2010;
Lusis and Weiss 2010; Vidal et al. 2011; Baryshnikova
et al. 2013). The networks are also responsive to exter-
nal and internal cues (Hancock et al. 2008, 2011; Coop et
al. 2009; Jackson and Bartek 2009). Further dimensions to
this variability is added by epigenetic changes and the enor-
mous human microbial diversity (Dolinoy and Jirtle 2008;
Human Microbiome Jumpstart Reference Strains Consortium
2010; Human Microbiome Project Consortium 2012; Cho
and Blaser 2012; Pflughoeft and Versalovic 2012). In addi-
tion to heritable variation, it is now acknowledged that an
individual’s genome is also patterned by a large number of
prezygotic de novo mutations, whose incidence is influenced
by the paternal age effect (PAE), as well as by transgen-
erational epigenetic inheritance (Goriely and Wilkie 2012;
Kong et al. 2012; Sharma 2013). Each individual is thus an
ecosystem harbouring a unique subset of variations and the
phenotype of an individual is the net outcome of the ecosys-
tem. A major challenge of systems biology is to differen-
tiate meaningful and functional variations from the neutral
ones, comprehend their cumulative effects at the systemwide
level, thereby linking them to phenotypes (Olson 2011, 2012;
Gibson and Visscher 2013; Visscher and Gibson 2013).
Major efforts have been made to link variation information
to many quantitative phenotypic traits like skin pigmenta-
tion, anthropomorphic features, physiological and metabolic
attributes and human adaptations (Katzmarzyk and Leonard
1998; Hancock et al. 2008; Jablonski and Chaplin 2010). All
such studies have provided a catalogue of genes and linked
biological processes as well as pathways, many of which are
assumed to shape human phenotypic attributes (Blake et al.
2009; Robinson and Mundlos 2010; Suhre et al. 2011). How-
ever, how they shape or integrate systems is still not well
understood.
Another aspect gaining importance is differences in the
association of biological variability with temporal cues such
as circadian, seasonal and other biological rhythms in an
individual (Roenneberg et al. 2007; Okamoto-Mizuno and
Mizuno 2012). It is now well established that there are
different biological clocks which are primarily set through
the suprachiasmatic nucleus (SCN) and mediated by per-
arnt-sim (PAS) domain containing proteins, while distinct
ontological processes have been observed to be enriched at
different times of the day (Merrow et al. 2005). Circadian
rhythms are intricately linked to metabolic homeostasis
which in turn is important for maintenance of cellular rhyth-
micity. Studies have revealed that there are inter-individual
differences in rhythmicity of expression of genes during dif-
ferent times of the day, season as well as with age (Touitou
et al. 1986; Okamoto-Mizuno and Mizuno 2012; Chua et al.
2013). For instance, variations in clock genes that associate
differently with sleep duration have been associated with dif-
ferent human chronotypes who have eveningness or morn-
ingness tendencies (Katzenberg et al. 1998; Roenneberg
et al. 2003; Wittmann et al. 2006). A recent RNA sequencing
study carried out on individuals throughout the year have
identified genes that exhibit different patterns of expression
during different seasons (Dopico et al. 2015).
Inter-individual differences in diurnal and metabolic
rhythms leading to different metabotypes have also been
reported (Morgan et al. 1998; Chua et al. 2013). It has also
been shown that intake of a high-fat diet not only disrupts the
normal circadian cycle but also causes a large scale genesis
of de novo oscillating transcripts, resulting in reorganization
of the coordinated oscillations between coherent transcripts
and metabolites (Hatori et al. 2012; Eckel-Mahan et al.
2013). Besides nutrition, irregularities in sleep, temperature
and so forth, lead to disruptions in these rhythms and have
been associated with susceptibility to diabetes, obesity and
cardiac disorders (Morgan et al. 1998; Wittmann et al. 2006;
Okamoto-Mizuno and Mizuno 2012). Genetic variants are
also linked to differences in the interaction between genes,
environment and nutrition (Lampe et al. 2013; Sales et al.
2014). Many genes that are responsive to temporal as well as
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environmental and nutrition factors also overlap with those
that shape human phenotypes and physiology. Despite this
huge body of information on genes, variation and pheno-
types, the connectivity from genetic determinants to pheno-
typic attributes of a system, its robustness and responsive-
ness to perturbations in an individualized perspective is still
lacking. Understanding human individuality would be a key
to defining baseline health states that is a prelude to precli-
nical and diseased states. This would enable development of
individualized tailored therapies that could help manage
health and disease.
East meets West: why prakriti should have genomic correlates?
There is much resistance and skepticism concerning the idea
that concepts of individuality as well as the basis for per-
sonalized medicine in Ayurveda can be explained by con-
temporary views of gene function and notions of causality
in disease. We see no fundamental contradiction between
the traditional medical practices outlined here, and genomic
medicine, and in fact consider it natural to expect that
there will be molecular genetics reason for the existence of
prakriti. One objective of personalized medicine is to clas-
sify individuals with respect to their risk of disease, which is
exactly the basis of ayurvedic practice. It may be argued that
Western medicine assumes that clinical traits are somewhat
independent and continuous such that there is no broad cat-
egorization of risk across multiple domains of health. How-
ever, we increasingly recognize that some people are at high
risk for metabolic disease or immune disease or mental health
problems. These categorizations are not necessarily equiva-
lent to those based on the dosha, but they point to an increas-
ing recognition that it may be possible to identify subclasses
of healthy people with subclinical tendencies.
From the reverse perspective, if we accept that in
Ayurveda, which has been practiced in India for over
5000 years, people adopt different diet/lifestyle practices
and even places and season most suitable to their prakriti
to remain healthy, then it is beholden upon us to look for
the underlying biochemical and physiological basis of this
individuality.
Strong candidates could be for instance, differences in
metabolic activity particularly relating to the flux of gluco-
neogenesis, oxidative phosphorylation, lipogenesis and pro-
tein biosynthesis; differences in the counts and state of activity
of diverse blood, immune and neuronal cell subtypes; and
variation in endocrine, cytokine and other systemic sig-
nalling systems. Variability in these core pathways contribute
to physiological differences between individuals and con-
nect to all major diseases. It is anticipated that these could
also differ between prakriti as they resonate with the phys-
iological attributes of vata, pitta and kapha. All of these
can be studied with high-throughput techniques such as tran-
scriptomics, metabolomics, lipidomics and flow cytometry.
Indeed, it is becoming apparent that there is very strong struc-
ture to gene expression profiles such that suites of hundreds
or even thousands of genes are coordinately regulated, and
relatively stable over time, unless perturbed under condi-
tions of disease (Chaussabel et al. 2010; Chen et al. 2012;
Preininger et al. 2013).
Finally, as outlined above, the prakriti are strongly deter-
mined at birth as a result of mixing of parental contribu-
tions, which we can now interpret as genotypes. It seems to
us perfectly reasonable to suppose that given a large enough
sample size, likely in the hundreds of thousands given the
scope of contemporary meta-analyses that genomewide asso-
ciation studies (GWAS) would start to identify genetic vari-
ants that associate with prakriti. In the following, we review
the one which is already discovered variant in EGLN1 that
was identified through a candidate gene approach to fit this
expectation. Although it is clear how genotypes can regulate
individual endophenotypes, it is not so conceptually straight
forward to appreciate how genotype effects combine together
to yield a small number of somewhat distinct physiological
states. This is where network biology needs to be integrated
with classical statistical genetics, which largely focusses on
the additive effects of individual genotypes on individual
traits.
Human phenotype phasing: need for reference scaffold
To comprehensively define a healthy individual in a popula-
tion, approaches are needed that can help apportion an indi-
vidual’s phenotypic variability into phenotypic phases that
could be (i) explained by ancestry, heritability, geographical
and climatic adaptations, (ii) due to de novo events, or (iii)
shaped by diet, environment and life style factors. Pheno-
typic phasing on these lines would reduce the dimensional-
ity of human variation to fewer axes of expression linked to
regulatory networks and aspects of human physiome.
It is evident that although the reductionist approach of
understanding the consequence of a genetic variant in a
model system often provides valuable mechanistic insights, it
is not contextual and is usually unable to provide explanation
for the whole integrated system (Noble 2002, 2008; 2011;
Auffray et al. 2009; Loscalzo and Barabasi 2011). However,
it is also true that with much complexity and connectivity
in readouts, identifying the parts that comprise the whole is
even a bigger challenge of integrating information of differ-
ent dimensions and scales across various cellular hierarchies
(Loscalzo and Barabási 2011; Olson 2012). This problem of
system biology is not trivial. Assembling a system from its
parts to reconstruct human phenotypes is analogous to, if
not more challenging than, sequencing and de novo assem-
bly of a genome. The task of this assembly becomes rela-
tively easier in the presence of a reference scaffold (Olson
2012). However, at present there are no phenotypic scaffolds
available and threading the networks from the genome to a
phenome is mostly a heuristic exercise.
Prakriti scaffolds for defining human individuality
Ayurveda phenotyping provides comprehensive analysis and
classification of individuals into seven broad prakriti groups.
These phenotype scaffolds could allow identification and
assembly of physiologically connected variations that can
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anchor networks from different scales and explain human
individuality. As described above, the diverse aspects that
have been dealt and observed independently to affect human
phenotypes and its responses are all considered cumulatively
and threaded together in defining an individual’s prakriti.
The second major aspect of this approach as described
in the earlier sections is the inherent weight given to
background factors that are considered during prakriti
assessment. For instance, assessment of height, skin pig-
mentation and other traits are considered in the context
of the baseline of the population from a particular eth-
nic background, ecocline and from a particular age group.
Thus, a person who would be qualified as tall or short,
dark or fair, is considered in the context of the popu-
lation background and not just as an objective measure.
Appreciation for evolving relative measures of baseline
values is gaining importance post GWAS (Yang et al.
2010; Olson 2012; Turchin et al. 2012). The most strik-
ing example is of height. There is nearly 80% heritability
in height. GWAS on height in a quarter million individuals
have identified over 400 loci that explains just 20% vari-
ance in height (Yang et al. 2010; Olson 2012; Turchin et al.
2012; Wood et al. 2014). Similar-sized studies of BMI and
waist-to-hip ratio have uncovered even less of the genetic,
∼100 and 50 variants each respectively, explaining less than
3% of the phenotypic variance. While much has been written
about the missing heritability problem, now it appears that
one of the major problems is simply lack of statistical power
to observe very small effect sizes.
It can be argued that one reason for the small effect sizes
is environmental (or epigenetic) heterogeneity. We recently
showed by simulation that if it is assumed that people live in
two different environments (for example, some adopt a more
healthy low calorie high activity lifestyle, others adopt the
typical modern high calorie sedentary one), then genotype–
environment interactions might readily be expected at the
level of genetic risk scores (that is, the cumulative effect of
alleles) even when it is not detectable for individual genotypes,
which is overwhelmingly the case (Marigorta and Gibson
2014). Importantly, it also appears that under these mixed
environment conditions, the power to detect genetic associ-
ations is decreased substantially because of the inflation of
phenotypic variance in the mixed population. The point is
that if in mixed environments, GWAS underperforms, the
ability to stratify individuals into subpopulations that are
more homogeneous should greatly increase the ability to
discover variants, some of which may be specific to sub-
populations. It should be apparent that prakriti can be con-
sidered as alternate environments within which genotypes
affect disease risk. Consequently, we propose that phenotypic
stratification based on principles of Ayurveda could feasi-
bly increase the resolution of GWAS under some circum-
stances (Juyal et al. 2012). A second aspect for these low
risk scores could be due to the difficulty in dissecting QTLs
or more important response QTLs in cross-sectional studies.
Since, prakriti of an individual also predicts the trajectory of
responsiveness to environmental cues, stratifying individuals
through prakriti could help resolve QTLs from a heteroge-
neous background. This can be tested through metaanalysis
of large expression datasets using prakriti specific signatures.
Additionally, in meta-analysis of GWAS, it has been
observed that power of association studies increases in mag-
nitude when the results are weighed on the basis of selection
signatures in associated variants (Kumar et al. 2011; Dudley
et al. 2012; Karlsson et al. 2014). Thus, it is possible that
many signals are already present in the data but the con-
textuality of these variations needs to be uncovered (Olson
2012). Many of these common variations have been linked to
human phenotypes and diseases that are also considered dur-
ing prakriti assessment. Characterization of different popu-
lation cohorts by prakriti methods could facilitate improved
identification of genomic polymorphisms linked to indepen-
dent phenotypic attributes, and their assembly into phenotype
scaffolds.
A third aspect that Ayurveda considers in assessing the
prakriti of an individual is adaptability to environment,
lifestyle, diet and drugs. Any deviation from an individ-
ual’s prakriti level is the perturbed state for that person
and the knowledge of the same is used for the treatment
of the individual. Since specific treatment regimes are con-
sidered to balance VPK as described earlier, therapeutic
interventions also need to be personalized. Thus, an indi-
vidual serves as a control for himself, and deviation from
his or her threshold provides an actionable point for each
individual.
Various methods for phenotypic classification such as
somatotypes, chronotypes, metabotypes and personality types
are available (Sheldon et al. 1940; Myers and McCaulley
1988; Roenneberg et al. 2003; Chua et al. 2013). Axes of
human gene expression variation on the basis of variability
in peripheral blood RNA expression have also been reported
recently (Preininger et al. 2013). In healthy adults, seven
common axes of variation are consistently observed, and
capture over half of the total variance in peripheral blood
gene expression. Each axis involves the coordinated regula-
tion of hundreds to thousands of genes that have functions
enriched for subtypes of immune function, from T-cell or B-
cell signalling to innate immunity and interferon response.
Each of us have measurable average level of expression of
genes in each axis, and these measures are relatively stable
over time. In pilot experiments, we have observed some cor-
respondence between these measures and prakriti, but more
work is needed to establish the robustness of the correla-
tions. It is also important to note that coordinated regula-
tion of gene expression along the axes is observed in other
tissues such as adipocytes and fibroblasts (Preininger et al.
2013), but the scores are only mildly correlated across indi-
viduals. This suggests that comprehensive matching of gene
expression to prakriti would require profiling of multiple tis-
sue types, which may not be practical. Certainly, a compre-
hensive assessment of individuality as described in Ayurveda
that encompasses different systems and connects it explicitly
to outcome in health and disease, not to mention their rela-
tion with personalized therapeutics, is not currently available
(Prasher et al. 2008).
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Linking human individuality to the natural evolution of disease
states
There have been a number of surprises in the course of iden-
tification of genes involved in monogenic and complex dis-
ease even where heritability of phenotypes and disease is
clearly observed (Loscalzo et al. 2007). For instance, the
concept of a single gene explaining a substantial fraction
of phenotypes in monogenic disorders has been challenged
(Kato et al. 2007, 2009). This is exemplified by the study
of variation in the β-globin gene implicated in sickle-cell
anaemia. Though this is the single largest implicated locus
in every sickle-cell patient, not all individuals carrying this
mutation exhibit the same clinical phenotypes. Thus there is
incomplete penetrance and variable expressivity (Raj et al.
2010). Roles for modifier genes interacting with the primary
mutation, leading to intermediate pathophenotypes in differ-
ent environment of hypoxia, infection and dehydration have
been implicated in this phenomenon (Kato et al. 2007, 2009).
Depending on the intermediate pathophenotypes there is a
difference in the course of the disease in an individual leading
to variability in symptoms like painful crisis, anaemia, stroke
chest pain, infarction etc. With the 1000 genomes sequencing
project it has become even more evident that predicting the
phenotypic outcome of a pathogenic mutation is going to
be a difficult exercise as a healthy individual on an aver-
age harbours nearly 100–200 predicted pathogenic variations
(O’Roak et al. 2011). Some, perhaps the majority of these
variants are false positive predictions but a large number
of them certainly have variable penetrance consistent with
extensive studies in model organisms (Polaczyk et al. 1998;
Barkoulas et al. 2013; Chari and Dworkin 2013). All these
factors reduce the predictive value of a primary mutation in
the absence of knowledge of modifiers, whose effects will
often be as complex as the genetics of traits such as height.
For complex diseases, a spate of GWAS has been success-
ful in explaining only a minor fraction of burden in diseases.
Notably, by definition, the explanation for risk to diseases
by the associated variants is for population rather than the
individual, i.e. it explains how many of the variation among
individuals can be attributed to the genetic polymorphism,
but does not say how many of the phenotype observed in
any given person is due to their genotypes. GWAS have not
only revealed that widely different pathways are linked to the
same disease but also different diseases to the same genes
with extensive cross talk between seemingly nonoverlapping
pathways. These observations could be best explained by the
existence of broad endo-phenotypes (corresponding geno-
types) that are differently predisposed to more than one dis-
ease and evolve into more discrete disease states through a
systemic response to stochastic and environmental cues. Phe-
WAS studies and big data mining from EMR records are pro-
viding corroborating observations (Shah et al. 2009; Barysh-
nikova et al. 2013; Marx 2013). However, there is as yet no
working road map to address health to disease transitions and
to predict which state of health could take which course of
disease. It is plausible that the thresholds for risk conferred
by variations are individual specific (Gibson 2012). The aver-
age effects observed in GWAS do not necessarily predict
effect sizes at the N= 1 level, as the same variant cannot
effect in some people and a large effect in others, averaging
to a small effect.
Since diseased individuals can be stratified on the basis
of prakriti, the integration of prakriti could afford a type
of phenotypic stratification that might facilitate identification
of core components of variation that could determine the
differential involvement of intermediate pathophenotypes
and thereby the course of disease (Sethi et al. 2011). For
instance, if reexamined from the perspective of Ayurveda,
the pathophenotypes described for sickle-cell anaemia, such
as painful crisis, thrombosis and haemolytic crisis, are also
described as predisposed phenotypes of aggravated vata,
kapha and pitta types respectively (1: C.Su.20; 2: S.Su.21).
It is therefore possible that inherent susceptibilities might
determine different phenotypic manifestation of the diseases
and therefore the integration of prakriti concepts into preclin-
ical condition might have a higher predictive value. It would
be worthwhile to reiterate that prakriti doshas can confer dif-
ferential robustness/susceptibility to the tissue or organ sys-
tems physiology. Therefore, the outcome of the samedisease
in different prakriti can have different manifestations.
Ayurgenomics approach for integration of human
individuality with P4 medicine
To integrate the trisutra concept of Ayurveda with genomic
methods, the first step would be to use a shared vocabu-
lary to denote the properties and interrelationships of these
concepts (shared ontological descriptions) in the language of
systems biology or modern network medicine. Therefore, we
hypothesize that the tridosha assessed using prakriti meth-
ods of phenotypic characterization of healthy individuals can
be associated with molecular and genomic correlates. As a
first step in testing this idea, we have studied genetic, gene
expression and biochemical profiles from peripheral blood
amongst prakriti types, to analyse and probe the ontologi-
cal links between doshas and molecular signatures (Prasher
et al. 2008). Similarly, others have observed differences in
immune cell type abundance associated with the prakriti
(Rotti et al. 2014) and a recent study also reports epigenetic
differences between prakriti types.
The study which was the first of its kind was carried
out in unrelated healthy individuals of predominant prakriti
belonging to an Indo-European genetic background from
north India in an age group of 19–40 years (Prasher et al.
2008). Genetic homogeneity in terms of the ethnic back-
ground of these individuals was established by a set of
genomewide neutral markers. Following this, genomewide
expression profiling was carried out on these individuals and
both the genders were analysed separately. At the biochem-
ical level, there were significant differences in lipid profiles,
liver functions, haematocrit, and blood clotting between the
constitution types, albeit within normal range. This high-
lights that the normal range of biochemical parameter for
different constitution types may be different, so also their
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subclinical ranges. Significant differences with respect to
genomewide expression were also observed between con-
trasting prakriti types. The genes that varied between the
groups mapped to core biological processes such as the cell
cycle, immune response, apoptosis and regulation of phys-
iological processes, metabolism and haemostasis. Many of
the differences resonated with the descriptions of Ayurveda
(1: C.Su.12, C.Su.18). It has been observed that although
interaction between genetic and environmental factors can
lead to multiple diseases and diversity of clinical phenotypes,
this may only happen through a finite number of intermedi-
ate pathophenotypes. Interestingly, all the processes that we
observed to differ between prakriti types overlap with the
intermediate pathophenotypes. The intermediate pathopheno-
types have been implicated in determining the progression
and subphenotypes in different diseases. This core result has
been observed in a replication cohort from a different ethnic
background (unpublished results).
It is thus possible that the baseline differences in healthy
individuals which are captured through prakriti phenotyping
could help us to classify individuals already at the preclinical
stage before they take a specific course through intermediate
pathophenotypes. Since prakriti concepts are linked to health
management, knowledge of an individual harbouring a pri-
mary mutation with a given prakriti could also be useful in
preventive aspects at the preclinical level. This assumes more
importance in scenarios where there is lack of availability of
appropriate drugs and the quality of life is severely compro-
mised with the progression of disease. Early identification of
perturbation could thus lead to preventive management dur-
ing preclinical stages, for instance in the context of metabolic
diseases such as atherosclerosis and type 2 diabetes or late
onset neurodegenerative disorders.
We observed significant overrepresentation of hubs and
housekeeping genes in the differentially expressed gene sets
in the prakriti groups. Hub genes are central to gene net-
works and variability in them could impact a large number
of functions and the genes linked in a network are good can-
didates to act as genetic modifiers (Barabási et al. 2011).
Since the method of prakriti phenotyping captures multiple
seemingly unconnected systems, genetic variation underly-
ing prakriti could enable identification of hub genes that
would have systemwide effects. Analysis of genetic varia-
tions in a subset of differentially expressed genes revealed a
significant set that differed between the prakriti types. Inci-
dentally, some of the genes that remained significant even
after FDR correction were core regulatory genes (FAS, AKT3,
EGLN1, RAD51, FBN2), variations in which are likely to
impact multiple phenotypes and functions (Aggarwal et al.
2010). It is now thought that primary disease mutations are
often members of peripheral nodes of disease gene networks
that interact with highly connected hubs, as a consequence of
which they have the capacity to contribute to diverse disease
processes. Since mutations in hubs are often lethal, probing
the involvement of hubs becomes a challenge. It is being
realized that methods needed to identify individuals at the
preclinical stage who are likely to progress differently to the
intermediate pathophenotypes are not available (Goh et al.
2007; Vidal et al. 2011). We propose that integration of
prakriti methods can help identify core and hub genes that
connect to multiple system phenotypes and are also respon-
sive to extrinsic and intrinsic cues. The readouts would be
the intermediate pathophenotypes but at the preclinical stage
that would decide the susceptibility and progression to dis-
eases depending on the expression of the peripheral genes.
Management of the disease would be more tractable if such
interconnectivities are identified.
We followed up EGLN1 (PHD2), a key oxygen sensor
which differed between pitta and kapha both at the expres-
sion and genetic level and was associated with high alti-
tude adaptation (97). EGLN1 expression was lower in pitta
compared to kapha and vata. The genotype linked to higher
expression in kapha was overrepresented in individuals who
suffered from high altitude pulmonary edema. The pitta-
linked genotype which correlates with higher basal levels
of HIF1a, was nearly fixed in natives of high altitude. The
observation of this gene being linked to high altitude adap-
tation has since been replicated in many global populations
(Pagani et al. 2012; Simonson et al. 2012; Bigham et al.
2013).
Maintenance of oxygen homeostasis is intricately linked to
development, growth and survival of an organism (Semenza
2011). The majority of the cellular responses in hypoxia
are mediated by a group of transcription factors called
the hypoxia inducible factors (HIFs). EGLN1 belongs to
the prolyl hydroxylase (PHD) group of proteins that under
well-oxygenated conditions become active and hydroxylate
HIF1a, which is then targeted for degradation by the von
Hippel-Lindau (VHL) proteasomal machinery (Ivan et al.
2001; Greer et al. 2012). In hypoxic conditions, EGLN1 is
inactive which in turn leads to stabilization of HIF1a. Acti-
vation of HIF1a leads to switching on of nearly 100–200
genes whose functions are required to cope with low oxygen
conditions (Kaelin and Ratcliffe 2008) (figure 4).
From our observation of differences in EGLN1 between
pitta and kapha prakriti, as well as from the growing
literature, we propose a conceptual similarity of EGLN1
with the organizing principle of tridosha. Table 4 and figure
4 highlight the multiple dimensions and scales at which
EGLN1 functions and lead us to argue that it satisfies the
criteria (as described in section ‘Ayurveda: translational
medicine with systems approach’) for it to be called a molec-
ular equivalent of tridosha. Briefly, EGLN1 has a role right
from foetal development through homeostasis in health and
disease (Kaelin and Ratcliffe 2008; Cheng et al. 2014; Duan
et al. 2014). Its rhythmic nature and responsiveness to intrin-
sic and extrinsic cues and autofeedback loop ensures its
expression and activity in physiological limits set by its
genetic make-up (Kaelin and Ratcliffe 2008; Hatori et al.
2012; Matsuura et al. 2013; Nguyen et al. 2013). Dysregula-
tion of this gene has been linked to diseases of multiple sys-
tems (Ladroue et al. 2008; Sen Banerjee et al. 2012; Franke
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Figure 4. Determinants and dynamics of EGLN1-HIF axis. (a) Triangle represents the baseline conditions in which EGLN1-HIF axis
normally operates with an auto-regulatory feedback mechanism in a temporal rhythmic manner. Ambient oxygen and cellular cues impact
the EGLN1-HIF axis which in turn modulates a large number of pathways. (b) In low oxygen condition, where EGLN1 is inactive, HIF
is stabilized leading to upregulation of pathways depicted. These resonate with the pitta functions. (c) In normoxic condition, EGLN1 is
active which leads to degradation of HIF resulting in down-regulation of HIF targeted pathways. The illustration depicts the various aspects
of EGLN1 given in table 4.
et al. 2013; Fujita et al. 2014). Model system studies indi-
cate that the biphasic nature of the PHD-HIF could modu-
late the outcome of many diseases (Natarajan et al. 2006;
Lee et al. 2008; Ahmad et al. 2012; Kiss et al. 2012; Sen
Banerjee et al. 2012). The extent of modulation of these pro-
cesses depends on the tissue, its oxygenation status, presence
of cofactors, levels of PHD2 and HIF, and other tissue-
specific transcriptional factors that work in conjunction with
HIF. It has also been shown to be a therapeutic target for sev-
eral diseases (Ziello et al. 2007; Haase 2010; Harten et al.
2010; Nagel et al. 2010; Ong and Hausenloy 2012; Kalucka
et al. 2013; Selvaraju et al. 2013; Zhao and Wu 2013; Soni
2014). Lower expression and subsequent stabilization of HIF
produces pitta-like molecular phenotypes whereas higher
expression might regulate kapha attributes (Aggarwal et al.
2010; Simonson et al. 2012).
Differential responsiveness to drugs is not only due to dif-
ferences in drug metabolizing enzymes or transporters (phar-
macokinetics), but also attributed to genetic differences in the
target proteins (pharmacodynamics) and more importantly
due to differential involvement of those targets/pathways in
pathogenesis of the disease occurring in an individual. This
is exemplified by the EGLN1 study, where different disease
conditions modulation of its expression can either favour
recovery like in ischaemia or aggravate the disease as in can-
cer. Genetic differences leading to inherent differences in
expression of this gene could not only modulate the disease
but could also be relevant in deciding the optimum dosage
for management of the disease. This is substantiated by our
recent observation wherein we have demonstrated a genetic
link between EGLN1 and VWF variations which can modu-
late the thrombotic outcome in response to hypoxic condition
(Aggarwal et al. 2015). This functional link assumes impor-
tance both in high altitude adaptation as well as conditions
of cellular hypoxia. Thus, integration of our understanding
of the principles of Ayurveda in drug discovery development
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Table 4. EGLN1 as a molecular correlate of tridosha. The table depicts the various characteristics of tridoshas which are fulfilled by the
functions of EGLN1 at the molecular level (Ivan et al. 2001; Natarajan et al. 2006; Ziello et al. 2007; Ladroue et al. 2008; Lee et al. 2008;
Aggarwal 2010; Harten et al. 2010; Semenza 2011; Ahmad et al. 2012; Kiss et al. 2012; Sen Banerjee et al. 2012, Franke et al. 2013;
Kalucka et al. 2013; Matsuura et al. 2013; Selvaraju et al. 2013. Duan et al. 2014; Fujita et al. 2014; Soni 2014).
Tridosha concordance Functional attribute Physiological activity Outcome
As an organizing Pervasive across Maintenance of Growth, development and survival of
principle systems oxygen homeostasis organism
Active from Development Role in development Involved in development of multiple
initiation from embryonic systems like heart, vasculature, hepatic,
stages retinal and skeletal system
Rhythmicity Pulsatile expression of Controls temporal Maintenance of dynamics of protein
HIF1a modulated by dynamics of HIF levels, its quantity and/or localization
PHD2 through PHD-HIF axis
Involved in • steady state Response to • Affects global transcription,
maintenance of sensing of • Low ambient translation, stress response and
homeostasis extrinsic oxygen signalling through PHD2-HIF axis
throughout environment and • Cellular hypoxia, •Modulation of core physiological
lifetime intrinsic factors low-ferrous iron, process regulated by HIF1a
TCA cycle Oxygen homeostasis in adult
intermediates - vascular system
fumarate, Erythropoiesis
succinate and 2 Angiogenesis,
oxoglutarate, NO, Anaerobic energy metabolism,
ROS, hormones Iron metabolism
• Response to Control of cell cycle and
ischemia proliferation
Apoptosis and autophagy
Redox homeostasis,
Inflammation
Immunity
Hematopoietic stem cell in
steady state and stress
Auto-feedback Regulation of PHD2 Reversal to homeostasis
expression by HIF or
activity by cellular
metabolites
Responsiveness to diet Inhibition of PHD2
and life style • By high salt intake • Induction of antihypertensive
mechanism via HIF1 activation
• Fat and glucose • Decreased glucose level and
reduced lipid accumulation
Genetic Adaptation and Baseline variability in Adaptation to high altitude is mediated
variability adaptability EGLN1 gene confers through ancestral allele linked to low
differences in PHD2 expression of PHD2
expression
Individuality Interindividual Genotypes linked to Might explain several linked
variability within the expression differs phenotypic attributes of prakriti
population between prakriti
Underlying Disease susceptibility Baseline variability, Protective where hypoxia is favoured
cause of progression, in response to and deleterious where its responses
health and prognosis, extrinsic and intrinsic favour pathogenesis
disease responsiveness to stimuli and their tissue-
therapy specific effects
Role in PHD-HIF axis as a Relevant in diseases 1. Cartilage repair
intervention therapeutic target where hypoxia is a 2. Wound healing improvement
cause or is 3. Arteriogenic phenotype
consequential in 4. Brain tumour
pathogenesis 5. Renal anaemia
6. Cardiovascular disease
7. Therapeutic revascularization after
visceral surgery
8. Myocardial ischemia
9. Recovery from stroke
10. Treatment of inflammatory diseases
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holds enormous potential, not just for predictive health
but also for personalized therapeutics (Patwardhan and
Mashelkar 2009; Dwivedi et al. 2012).
Ayurgenomics: an operational framework for integrating the
trisutra concepts with modern medicine  
1. Basic tenets of Ayurveda are highlighted, showing how the
personalized, predictive, preventive and participatory
aspects parallel P4 medicine 
2. Network medicine with a systems approach includes
discussion of how:  
a. interlinks  between  cause  (hetu),  feature  (linga) and
therapeutics  (aushadha)  in  trisutra  form  the basis
for translational medicine 
b. a  common  organizing  principle,  tridosha,  connects
the three axes of trisutra 
c. expression  of  tridoshas  is  evident  at  different levels
of organization 
d. variability  in  tridosha  during  development  governs
inter-individual differences leading to seven broad
prakriti types in a population 
e. dynamic components of tridosha link health and
disease in response to external and internal 
environmental agents 
f. understanding  of  human  individuality  forms  the  core
for personalized management of health and disease
3. Prakriti provide phenotype scaffolds through P-P links for 
a. understanding human individuality   
b. stratification of individuals irrespective of
population labels 
4. Prakriti are likely to have genomic correlates e.g immune,
metabolic and neurophysiological gene activity  
5. Genetic and genomic analyses show how EGLN1 could be
an example of a  molecular contributor to tridosha
Concluding remarks
The identification of genes and pathways involved in devel-
opment and manifestation of variable states of health, disease
and responsiveness to drugs within and across populations
will be crucial to integration of personalized approaches in
drug discovery and development. This would also simultane-
ously facilitate development of biomarker-based drug deliv-
ery in a personalized manner. Trisutra, thus is an operational
framework for translational aspects of network medicine
with systems understanding. It can also provide a theoretical
framework for integrating basic understanding at the systems
level with outcomes in health and disease and development
of personalized prevention and therapeutics.
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